Form 4 for IDXX Idexx Laboratories
Accepted 2024-02-16 00:00:00 ET · period of report 2024-02-14 · accession 0000874716-24-000039 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-16 | 2024-02-14 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | M - OptEx | $0.00 | +4,156 | 79.7K | +6% | $0 |
| D | 2024-02-16 | 2024-02-14 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | F - Tax | $560.56 | -1,839 | 81.6K | -2% | -$1.03M |
| DM | 2024-02-16 | 2024-02-14 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | M - OptEx | $0.00 | -4,156 | 0 | -100% | $0 |
| DM | 2024-02-16 | 2024-02-14 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | A - Grant | $0.00 | +21.5K | 21.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-14 | M | A | 1,100 | $0.00 | 83,402.59 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-14 | M | A | 958 | $0.00 | 82,302.59 | D | — | — | |
| 3 | Common | Common Stock | 2024-02-14 | M | A | 689 | $0.00 | 81,344.59 | D | — | — | |
| 4 | Common | Common Stock | 2024-02-14 | M | A | 974 | $0.00 | 80,655.59 | D | — | — | |
| 5 | Common | Common Stock | 2024-02-14 | M | A | 435 | $0.00 | 79,681.59 | D | — | — | |
| 6 | Common | Common Stock | 2024-02-14 | F | D | 1,839 | $560.56 | 81,563.59 | D | — | — | |
| 7 | Derivative | Restricted Stock Unit | 2024-02-14 | M | D | 1,100 | $0.00 | 3,298 | D | — · — to — | 1,100 Common Stock | (F7) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. |
| 8 | Derivative | Restricted Stock Unit | 2024-02-14 | M | D | 958 | $0.00 | 1,916 | D | — · — to — | 958 Common Stock | (F6) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. |
| 9 | Derivative | Restricted Stock Unit | 2024-02-14 | M | D | 689 | $0.00 | 689 | D | — · — to — | 689 Common Stock | (F5) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. |
| 10 | Derivative | Restricted Stock Unit | 2024-02-14 | M | D | 974 | $0.00 | 0 | D | — · — to — | 974 Common Stock | (F4) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2021. |
| 11 | Derivative | Restricted Stock Unit | 2024-02-14 | M | D | 435 | $0.00 | 0 | D | — · — to — | 435 Common Stock | (F3) Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2020. |
| 12 | Derivative | Incentive Stock Option (right-to-buy) | 2024-02-14 | A | A | 178 | $0.00 | 178 | D | $560.56 · — to 2034-02-13 | 178 Common Stock | (F2) Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2028. |
| 13 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2024-02-14 | A | A | 21,335 | $0.00 | 21,335 | D | $560.56 · — to 2034-02-13 | 21,335 Common Stock | (F1) Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2025. |